Transaction #18310 · Form 4 · 0001159036-25-000073
HALOZYME THERAPEUTICS, INC. · Stock award · Performance Stock Units
HALOZYME THERAPEUTICS, INC. · Transacted December 9, 2025 · Filed December 11, 2025
What does this filing report?
An SEC Form 4 filing for HALOZYME THERAPEUTICS, INC. records a stock award involving Performance Stock Units on December 9, 2025. The reported quantity was 165,522. The filing date is December 11, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- HALOZYME THERAPEUTICS, INC.
- Company CIK
- 0001159036
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 165,522
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 165,522
- Ownership description
- Not reported
- SEC acceptance time
- Dec 11, 2025, 6:16 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Torley Helen ↗
PRESIDENT AND CEO · Director
CIK 0001528185
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 165,522
- Conversion / exercise price
- 0
- Exercise date
- Not reported
- Expiration date
- Not reported
Filing footnotes & remarks
- F1
- Represents the grant of performance-based vesting Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of HALO common stock. The target number of Restricted Stock Units subject to the award is indicated. Up to two hundred percent (200%) of the target Restricted Stock Units could vest if the average closing price of HALO common stock over a period of 20 consecutive trading days during a four-year performance period following the grant of the award equals or exceeds certain price levels specified in the award (with 50% of target number of units vesting at $115 and an additional 50% of the target number of units vesting at each of $130, $145 and $170) and, in each case, only if the Reporting Person remains employed with the Registrant through the end of the performance period (subject to certain exceptions provided in the applicable award agreement).
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.